VALERIE JANSEN: Open Payments
NPI 1437172764 · LENEXA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,711 in 99 payments from 15 companies in 2025. Trend: 2023 $1,059 · 2024 $849 · 2025 $1,711
Food & beverage: $1,704Education: $7
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $407 |
| Vanda Pharmaceuticals Inc. | 16 | $303 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $241 |
| Axsome Therapeutics, Inc. | 9 | $194 |
| Tris Pharma Inc | 10 | $159 |
| Otsuka America Pharmaceutical, Inc. | 5 | $99 |
| E.R. Squibb & Sons, L.L.C. | 5 | $95 |
| Alkermes, Inc. | 2 | $40 |
| Noven Therapeutics, LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
Products named: VRAYLAR, CAPLYTA, HETLIOZ, Auvelity, Dyanavel XR, REXULTI, COBENFY, FANAPT.
Industry payments across KS — which companies pay providers there.
